Patient preferences for attributes of tyrosine kinase inhibitor treatments for EGFR mutation-positive non-small-cell lung cancer
| Autor: | Marie de la Cruz, Ancilla W. Fernandes, Emuella Flood, Nabil Chehab, Melissa Pavilack, John F.P. Bridges, Ellen M. Janssen |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Diarrhea
Male Oncology Cancer Research medicine.medical_specialty Lung Neoplasms Time Factors Vomiting medicine.drug_class Administration Oral Discrete choice experiment Severity of Illness Index Tyrosine-kinase inhibitor 03 medical and health sciences 0302 clinical medicine Carcinoma Non-Small-Cell Lung Surveys and Questionnaires Internal medicine medicine Humans Dosing Lung cancer Protein Kinase Inhibitors Fatigue Aged Retrospective Studies Aged 80 and over business.industry 030503 health policy & services Dosing regimen Nausea Patient Preference General Medicine Middle Aged medicine.disease Patient preference Progression-Free Survival ErbB Receptors Egfr mutation 030220 oncology & carcinogenesis Mutation Female Non small cell 0305 other medical science business |
| Zdroj: | Future Oncology. 15:3895-3907 |
| ISSN: | 1744-8301 1479-6694 |
| DOI: | 10.2217/fon-2019-0396 |
| Popis: | Aim: EGFR-tyrosine kinase inhibitors (TKIs) vary in efficacy, side effects (SEs) and dosing regimen. We explored EGFR-TKI treatment attribute preferences in EGFR mutation-positive metastatic non-small-cell lung cancer. Materials & methods: Patients completed a survey utilizing preference elicitation methods: direct elicitation of four EGFR-TKI profiles describing progression-free survival (PFS), severe SE risk, administration; discrete choice experiment involving 12 choice tasks. Results: 90 participated. The preferred profile (selected 89% of times) had the longest PFS (18 months) and the lowest severe SE risk (5%). Patients would need compensation with ≥three-times longer PFS for severe SEs. Patients would accept ≤7 months PFS reduction for oral treatments versus intravenous. Conclusion: Patients preferred longer PFS but were willing to accept reduced PFS for more favorable SEs and dosing convenience. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|